ACM
CALA

Altium Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Altium Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,114
Closed -$82K – 146
2022
Q1 		$82K Buy
+10,114
New +$103K 0.03% 105
2021
Q2 		– Sell
-42,695
Closed -$2.07M – 170
2021
Q1 		$2.07M Buy
+42,695
New +$2.48M 0.57% 74

Other funds holding CALA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altium Capital Management's CALA Position: Q2 2022 in Review

Altium Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 10,114 shares — an estimated $82K sold.

Altium Capital Management first reported a position in CALA in Q1 2021 and held it in 2 quarters. The position peaked at $2.07M in Q1 2021. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

  • Altium Capital Management reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
  • Altium Capital Management sold 10,114 Calithera Biosciences, Inc shares in Q2 2022, an estimated $82K.
  • Altium Capital Management first reported a position in Calithera Biosciences, Inc in Q1 2021 and held it in 2 quarters.
  • Altium Capital Management's Calithera Biosciences, Inc position peaked at $2.07M in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.